

# STATISTICAL COMPENDIUM: MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT IN 2003 GEORGIA

## LIST OF TABLES

### OVERVIEW OF STUDY POPULATION

TABLE 1. OVERVIEW OF BENEFICIARY SELECTION CRITERIA FOR STUDY POPULATION

### FOR ALL MEDICAID BENEFICIARIES

- TABLE 2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY
- TABLE 3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC
- TABLE 4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC
- TABLE 5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC
- TABLE 6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY
- TABLE 7. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP

### FOR ALL NONDUAL BENEFICIARIES

- TABLE ND.2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY
- TABLE ND.3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC
- TABLE ND.4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC
- TABLE ND.5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC
- TABLE ND.6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY
- TABLE ND.7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP
- TABLE ND.8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC
- TABLE ND.9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BRAND STATUS AND THERAPEUTIC CATEGORY
- TABLE ND.10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY TOP 10 DRUG GROUP
- TABLE ND.11. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS, BY BENEFICIARY CHARACTERISTIC
- TABLE ND.12. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC
- TABLE ND.13. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES AMONG NONDUALS

## **FOR DUAL ELIGIBLE BENEFICIARIES**

TABLE D.2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY

TABLE D.3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC

TABLE D.4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT *PER BENEFIT MONTH*, BY BENEFICIARY CHARACTERISTIC

TABLE D.5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC

TABLE D.6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE D.7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP

TABLE D.8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC

TABLE D.9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE D.10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY TOP 10 DRUG GROUP

TABLE D.11. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG DUALS, BY BENEFICIARY CHARACTERISTIC

TABLE D.12. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG DUALS PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC

TABLE D.13. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES AMONG DUALS

## **SUPPLEMENTAL TABLES**

SUPPLEMENTAL TABLE 1. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES

SUPPLEMENTAL TABLE 1A. MEDICAID PHARMACY REIMBURSEMENT FOR DISABLED DUAL ELIGIBLE BENEFICIARIES UNDER AGE 65

SUPPLEMENTAL TABLE 1B. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 AND OLDER

SUPPLEMENTAL TABLE 1C. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 TO 74

SUPPLEMENTAL TABLE 1D. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 75 TO 84

SUPPLEMENTAL TABLE 1E. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 85 AND OLDER

## **APPENDIX TABLES**

APPENDIX TABLE A.1. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY, NONDUAL BENEFICIARIES

APPENDIX TABLE A.2. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS, NONDUAL BENEFICIARIES

APPENDIX TABLE A.3. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY, DUAL ELIGIBLE BENEFICIARIES

APPENDIX TABLE A.4. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS, DUAL ELIGIBLE BENEFICIARIES

TABLE ND.2

CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY<sup>a,b</sup>  
 NONDUAL BENEFICIARIES, GEORGIA, 2003

Beneficiary Characteristics	Number of Beneficiaries							Number of Benefit Months											
	All	Aged	Disabled	Adults	Children	Other/ Unknown	All	Aged	Disabled	Adults	Children	Other/ Unknown	All	Aged	Disabled	Adults	Children	Other/ Unknown	
<b>All</b>	<b>1,397,022</b>	<b>5,963</b>	<b>151,025</b>	<b>281,777</b>	<b>958,257</b>	<b>0</b>	<b>12,578,532</b>	<b>55,047</b>	<b>1,616,161</b>	<b>2,057,249</b>	<b>8,850,075</b>	<b>0</b>	<b>12,578,532</b>	<b>55,047</b>	<b>1,616,161</b>	<b>2,057,249</b>	<b>8,850,075</b>	<b>0</b>	
<b>Age</b>																			
5 and younger	457,748	0	10,819	64	446,865	0	4,107,866	0	112,671	475	3,994,720	0	4,107,866	0	112,671	475	3,994,720	0	
6-14	404,245	0	23,252	249	380,744	0	3,931,012	0	260,811	1,761	3,668,440	0	3,931,012	0	260,811	1,761	3,668,440	0	
15-20	181,642	69	14,311	37,154	130,108	0	1,614,342	602	159,778	271,753	1,182,209	0	1,614,342	602	159,778	271,753	1,182,209	0	
21-44	276,820	1,035	43,600	231,693	492	0	2,168,489	9,463	468,759	1,686,007	4,260	0	2,168,489	9,463	468,759	1,686,007	4,260	0	
45-64	70,497	977	56,957	12,547	16	0	696,793	9,024	590,951	96,677	141	0	696,793	9,024	590,951	96,677	141	0	
65-74	3,478	1,672	1,784	21	1	0	34,958	14,940	19,900	116	2	0	34,958	14,940	19,900	116	2	0	
75-84	1,735	1,464	268	2	1	0	17,146	14,172	2,946	16	12	0	17,146	14,172	2,946	16	12	0	
85 and older	856	746	34	46	30	0	7,917	6,846	345	435	291	0	7,917	6,846	345	435	291	0	
Unknown	1	0	0	1	0	9	0	0	0	9	0	0	0	0	0	9	0	0	0
<b>Gender</b>																			
Female	816,882	4,636	77,397	260,190	474,659	0	7,196,729	42,823	839,537	1,920,396	4,393,973	0	7,196,729	42,823	839,537	1,920,396	4,393,973	0	
Male	580,118	1,327	73,627	21,587	483,577	0	5,381,680	12,224	776,612	136,853	4,455,991	0	5,381,680	12,224	776,612	136,853	4,455,991	0	
Unknown	22	0	1	0	21	0	123	0	12	0	111	0	123	0	12	0	111	0	
<b>Race</b>																			
White	567,008	2,568	52,686	125,822	385,932	0	4,851,702	22,803	550,953	833,550	3,444,396	0	4,851,702	22,803	550,953	833,550	3,444,396	0	
African American	703,422	1,669	66,293	147,452	488,008	0	6,593,444	15,154	719,328	1,173,336	4,685,626	0	6,593,444	15,154	719,328	1,173,336	4,685,626	0	
Other/unknown	126,592	1,726	32,046	8,503	84,317	0	1,133,386	17,090	345,880	50,363	720,053	0	1,133,386	17,090	345,880	50,363	720,053	0	
<b>Use of Nursing Facilities<sup>c</sup></b>																			
Entire year	2,021	677	1,344	0	0	0	21,124	6,879	14,245	0	0	0	21,124	6,879	14,245	0	0	0	
Part year	1,440	347	1,088	4	1	0	14,358	3,049	11,261	36	12	0	14,358	3,049	11,261	36	12	0	
None	1,393,561	4,939	148,593	281,773	958,256	0	12,543,050	45,119	1,590,655	2,057,213	8,850,063	0	12,543,050	45,119	1,590,655	2,057,213	8,850,063	0	
<b>Maintenance Assistance Status</b>																			
Cash	489,410	1,508	125,397	127,791	234,714	0	4,716,891	16,784	1,388,528	1,020,358	2,291,221	0	4,716,891	16,784	1,388,528	1,020,358	2,291,221	0	
Medically needy	4,489	807	3,623	1	58	0	24,846	5,524	19,186	1	135	0	24,846	5,524	19,186	1	135	0	
Poverty-related	676,190	2,127	36	109,162	564,865	0	5,891,407	19,478	349	658,766	5,212,814	0	5,891,407	19,478	349	658,766	5,212,814	0	
Other/unknown	226,933	1,521	21,969	44,823	158,620	0	1,945,388	13,261	208,098	378,124	1,345,905	0	1,945,388	13,261	208,098	378,124	1,345,905	0	
<b>Managed Care (MC) Status</b>																			
Fee-for-service (FFS) all year	1,397,022	5,963	151,025	281,777	958,257	0	12,578,532	55,047	1,616,161	2,057,249	8,850,075	0	12,578,532	55,047	1,616,161	2,057,249	8,850,075	0	
FFS part year, with Rx claims	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FFS part year, no Rx claims	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Table ND2

Nondual Beneficiaries

Source: Data for this table are from the MAX 2003 file for Georgia, released by CMS in 04/2007. This table was produced on 11/01/2007.

- a. Table ND.2 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.
- c. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; Rx = pharmacy benefit.

TABLE ND.3

ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC<sup>a, b</sup>  
NONDUAL BENEFICIARIES, GEORGIA, 2003

Beneficiary Characteristics	Percentage with at Least One Rx	Mean Number of Rx	Mean Rx \$	\$ per Rx	Mean \$, All Medicaid FFS \$ <sup>c</sup>	Rx \$ as a Percentage of All Medicaid FFS \$ <sup>d</sup>	Number of Beneficiaries
All	66.9 %	8.1	\$422	\$52	\$2,641	16.0 %	1,397,022
<b>Age</b>							
5 and younger	70.4	5.6	220	39	1,919	11.5	457,748
6-14	60.0	5.0	282	57	1,362	20.7	404,245
15-20	62.0	5.6	302	54	2,274	13.3	181,642
21-44	71.1	10.4	572	55	3,904	14.6	276,820
45-64	78.9	36.8	2,148	58	9,870	21.8	70,497
65-74	80.3	36.9	1,847	50	11,326	16.3	3,478
75-84	80.6	35.0	1,690	48	10,939	15.5	1,735
85 and older	77.5	33.8	1,430	42	14,406	9.9	856
Unknown	100.0	1.0	42	42	108	38.9	1
<b>Basis of Eligibility<sup>e</sup></b>							
Aged	81.0	28.3	1,544	55	12,610	12.2	5,963
Disabled	78.0	27.8	1,961	70	9,593	20.4	151,025
Adults	70.8	7.9	299	38	2,855	10.5	281,777
Children	63.9	4.9	209	43	1,420	14.7	958,257
Unknown	0.0	0.0	0	0	0	0.0	0
<b>Gender</b>							
Female	68.9	8.8	422	48	2,743	15.4	816,882
Male	64.2	7.1	422	60	2,498	16.9	580,118
Unknown	22.7	2.5	79	32	928	8.6	22
<b>Race</b>							
White	71.3	9.6	494	51	2,875	17.2	567,008
African American	64.1	6.6	332	51	2,237	14.8	703,422
Other/unknown	62.9	9.5	600	63	3,843	15.6	126,592
<b>Use of Nursing Facilities<sup>f</sup></b>							
Entire year	97.2	68.7	4,006	58	43,619	9.2	2,021
Part year	96.0	62.7	3,748	60	43,676	8.6	1,440
None	66.8	7.9	414	52	2,539	16.3	1,393,561
<b>Maintenance Assistance Status</b>							
Cash	70.3	12.6	747	59	3,680	20.3	489,410
Medically needy	61.1	18.8	1,290	69	12,120	10.6	4,489
Poverty related	63.7	4.8	191	40	1,574	12.1	676,190
Other/unknown	69.4	7.8	393	50	3,392	11.6	226,933

Table ND3

Nondual Beneficiaries

Source: Data for this table are from the MAX 2003 file for Georgia, released by CMS in 04/2007. This table was produced on 11/01/2007.

- a. Table ND.3 includes beneficiaries represented by Cell K of Table 1.
  - b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
  - c. In seven states (DE, IA, NE, NY, TX, UT, and WV) the expenditures in this column include only Rx drug expenditures for those enrolled in capitated managed care plans, and not expenditures for other services covered by the plans or long-term-care services not covered by the plans. As a result, the amounts shown in this column for all Medicaid fee-for-service expenditures are lower than they would otherwise be.
  - d. In seven states (DE, IA, NE, NY, TX, UT, and WV) the Rx share of expenditures for all Medicaid services shown in this column is higher than it would be if all expenditures for these other services, including services provided in capitated managed care plans and long-term-care services, were included.
  - e. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
  - f. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.
- Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.4  
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC<sup>a,b</sup>  
 NONDUAL BENEFICIARIES, GEORGIA, 2003

Beneficiary Characteristics	Number of Rx. Percentage with:										Number	
	Mean Number of Rx	Mean Rx \$	Percentage of All Medicaid FFS <sup>c</sup>	None	More than 0, but 1 or Less	1, but 2 or Less	2, but 5 or Less	5, but 10 or Less	More than 10	Mean \$, All Medicaid FFS <sup>d</sup>	Beneficiaries	Benefit Months
All	0.9	\$47	16.0 %	33.1 %	51.1 %	7.8 %	5.8 %	1.8 %	0.4 %	\$293	1,397,022	12,578,552
<b>Age</b>												
5 and younger	0.6	25	11.5	29.6	59.7	7.6	2.9	0.2	0.0	214	457,748	4,107,866
6-14	0.5	29	20.7	40.0	51.3	5.2	3.2	0.4	0.0	140	404,245	3,931,012
15-20	0.6	34	13.3	38.0	50.5	7.0	4.0	0.6	0.0	256	181,642	1,614,342
21-44	1.3	73	14.6	28.9	46.0	11.6	10.2	2.9	0.4	498	276,820	2,168,489
45-64	3.7	217	21.8	21.1	19.2	11.0	25.3	18.4	5.1	999	70,497	696,793
65-74	3.7	184	16.3	19.7	18.1	10.6	29.2	18.5	3.9	1,127	3,478	34,958
75-84	3.5	171	15.5	19.4	17.8	11.5	28.9	17.6	5.0	1,107	1,735	17,146
85 and older	3.7	155	9.9	22.5	13.9	9.9	29.0	20.8	3.9	1,558	856	7,917
Unknown	0.1	5	38.9	0.0	100.0	0.0	0.0	0.0	0.0	12	1	9
<b>Basis of Eligibility<sup>e</sup></b>												
Aged	3.1	167	12.2	19.0	24.8	13.3	26.8	13.3	2.9	1,366	5,963	55,047
Disabled	2.6	183	20.4	22.0	30.6	11.6	20.8	11.9	3.0	896	151,025	1,616,161
Adults	1.1	41	10.5	29.2	49.4	11.4	8.1	1.7	0.2	391	281,777	2,057,249
Children	0.5	23	14.7	36.1	55.0	6.1	2.6	0.2	0.0	154	958,257	8,850,075
Unknown	0.0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0	0	0
<b>Gender</b>												
Female	1.0	48	15.4	31.1	51.5	8.3	6.3	2.2	0.5	311	816,882	7,196,729
Male	0.8	46	16.9	35.8	50.5	7.1	5.1	1.3	0.2	269	580,118	5,381,680
Unknown	0.4	14	8.6	77.3	18.2	0.0	4.5	0.0	0.0	166	22	123
<b>Race</b>												
White	1.1	58	17.2	28.7	51.2	9.6	7.5	2.4	0.6	336	567,008	4,851,702
African American	0.7	35	14.8	35.9	52.0	6.4	4.3	1.2	0.2	239	703,422	6,593,444
Other/unknown	1.1	67	15.6	37.1	45.5	7.4	6.8	2.7	0.6	429	126,592	1,133,386
<b>Use of Nursing Facilities<sup>f</sup></b>												
Entire year	6.6	383	9.2	2.8	5.3	6.6	29.6	40.3	15.3	4,173	2,021	21,124
Part year	6.3	376	8.6	4.0	8.0	8.4	28.6	36.9	14.1	4,380	1,440	14,358
None	0.9	46	16.3	33.2	51.2	7.8	5.7	1.7	0.3	282	1,393,561	12,543,050
<b>Maintenance Assistance Status</b>												
Cash	1.3	78	20.3	29.7	47.3	8.7	9.4	4.0	0.9	382	489,410	4,716,891
Medically needy	3.4	233	10.6	38.9	13.5	9.4	21.1	14.0	3.2	2,190	4,489	24,846
Poverty related	0.6	22	12.1	36.3	53.8	6.8	2.9	0.2	0.0	181	676,190	5,891,407
Other/unknown	0.9	46	11.6	30.6	52.2	9.0	6.3	1.5	0.3	396	226,933	1,945,388

Source: Data for this table are from the MAX 2003 file for Georgia, released by CMS in 04/2007. This table was produced on 11/01/2007.

- a. Table ND.4 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
  - b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
  - c. In seven states (DE, IA, NE, NY, TX, UT, and WV) the expenditures in this column include only Rx drug expenditures for those enrolled in capitated managed care plans, and not expenditures for other services covered by the plans or long-term-care services not covered by the plans. As a result, the amounts shown in this column for all Medicaid fee-for-service expenditures are lower than they would otherwise be.
  - d. In seven states (DE, IA, NE, NY, TX, UT, and WV) the Rx share of expenditures for all Medicaid services shown in this column is higher than it would be if all expenditures for these other services, including services provided in capitated managed care plans and long-term-care services, were included.
  - e. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
  - f. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.
- Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.



TABLE ND.5  
 AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC<sup>a, b, c</sup>  
 NONDUAL BENEFICIARIES, GEORGIA, 2003

Beneficiary	All Rx			Patented Brand-Name Drugs			Off-Patent Brand-Name Drugs			Generic Drugs		
	Number of Rx	Rx \$	\$ per Rx	Number of Rx	Rx \$	\$ per Rx	Number of Rx	Rx \$	\$ per Rx	Number of Rx	Rx \$	\$ per Rx
<b>All</b>	<b>0.9</b>	<b>\$47</b>	<b>\$52</b>	<b>0.4</b>	<b>\$38</b>	<b>\$90</b>	<b>0.0</b>	<b>\$1</b>	<b>\$35</b>	<b>0.4</b>	<b>\$8</b>	<b>\$18</b>
<b>Age</b>												
5 and younger	0.6	25	39	0.3	19	68	0.0	1	28	0.3	4	14
6-14	0.5	29	57	0.3	24	84	0.0	1	45	0.2	4	20
15-20	0.6	34	54	0.3	27	90	0.0	1	39	0.3	6	19
21-44	1.3	73	55	0.6	58	105	0.0	2	36	0.7	13	17
45-64	3.7	217	58	1.7	174	104	0.1	4	36	1.9	39	20
65-74	3.7	184	50	1.7	144	85	0.1	4	29	1.8	35	19
75-84	3.5	171	48	1.6	135	83	0.1	4	26	1.8	32	18
85 and older	3.7	155	42	1.5	116	76	0.2	5	24	1.9	33	17
Unknown	0.1	5	42	0.1	5	42	0.0	0	0	0.0	0	0
<b>Basis of Eligibility<sup>d</sup></b>												
Aged	3.1	167	55	1.4	136	97	0.1	3	26	1.5	27	18
Disabled	2.6	183	70	1.2	151	124	0.1	4	47	1.3	28	22
Adults	1.1	41	38	0.4	31	71	0.0	1	24	0.6	9	15
Children	0.5	23	43	0.3	18	69	0.0	1	32	0.2	4	16
Unknown	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0
<b>Gender</b>												
Female	1.0	48	48	0.4	38	84	0.0	1	33	0.5	9	17
Male	0.8	46	60	0.4	37	100	0.0	1	40	0.3	7	19
Unknown	0.4	14	32	0.1	11	80	0.0	1	22	0.2	2	9
<b>Race</b>												
White	1.1	58	51	0.5	46	88	0.1	2	36	0.5	10	18
African American	0.7	35	51	0.3	29	88	0.0	1	33	0.3	6	17
Other/unknown	1.1	67	63	0.5	55	108	0.0	2	42	0.5	10	20
<b>Use of Nursing Facilities<sup>e</sup></b>												
Entire year	6.6	383	58	2.7	299	111	0.4	13	33	3.5	71	20
Part year	6.3	376	60	2.5	291	115	0.4	13	37	3.4	71	21
None	0.9	46	52	0.4	37	90	0.0	1	35	0.4	8	18
<b>Maintenance Assistance Status</b>												
Cash	1.3	78	59	0.6	63	105	0.0	2	40	0.7	13	19
Medically needy	3.4	233	69	1.5	186	121	0.1	4	34	1.7	41	24
Poverty related	0.6	22	40	0.3	17	65	0.0	1	29	0.2	4	15
Other/unknown	0.9	46	50	0.4	37	87	0.0	1	35	0.4	7	16

Table ND5

Nondual Beneficiaries

Source: Data for this table are from the MAX 2003 file for Georgia, released by CMS in 04/2007. This table was produced on 11/01/2007.

- a. Table ND.5 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. In Georgia, 0.9 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all combined. For information about this classification method, see Wolters Kluwer Health, <http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).
- d. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- e. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.6

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY<sup>a, b, c, d</sup>  
 NONDUAL BENEFICIARIES, GEORGIA, 2003

Therapeutic Category	Number of Rx per Benefit Month Among Users				\$ per Benefit Month Among Users				Users <sup>e</sup>						
	Total	Patented Brand-Name	Off-Patent Brand-Name	Generic	Total	Patented Brand-Name	Off-Patent Brand-Name	Generic	Total Number of Rx	Total Rx \$	Number of Users	Percentage of All Beneficiaries	As a Percentage	Number of Benefit Months	
															Total
Anti-infective Agents	0.3	0.1	0.0	0.1	\$13	\$10	\$0	\$2	\$50	\$64	\$19	1,715,175	637,933	45.7 %	6,543,357
Biologicals	0.5	0.5	0.0	0.0	735	641	20	74	1363	3,290	2,985	15,394	3,161	0.2	28,543
Antineoplastic Agents	0.5	0.2	0.0	0.2	134	116	2	16	292	512	147	21,537	4,471	0.3	46,920
Endocrine/Metabolic Drugs	0.4	0.2	0.0	0.1	16	13	1	2	43	62	24	839,319	225,247	16.1	2,302,780
Cardiovascular Agents	1.1	0.5	0.0	0.6	40	30	0	9	36	64	21	1,033,271	89,863	6.4	942,483
Respiratory Agents	0.4	0.2	0.0	0.2	16	12	1	3	40	65	23	2,284,030	564,770	40.4	5,844,150
Gastrointestinal Agents	0.4	0.1	0.0	0.2	20	13	1	5	54	107	166	451,359	120,893	8.7	1,240,360
Genitourinary Agents	0.2	0.2	0.0	0.0	9	8	0	0	41	47	25	162,379	78,832	5.6	766,700
CNS Drugs	0.7	0.4	0.0	0.3	60	54	1	5	89	140	73	1,115,371	159,511	11.4	1,666,618
Stimulants/Anti-obesity/Anorexia	0.6	0.5	0.0	0.1	44	39	1	4	74	83	55	343,914	52,877	3.8	573,234
Miscellaneous Psychological/Neurological Agents	0.5	0.3	0.0	0.2	84	80	0	4	168	232	10	10,851	2,016	0.1	21,781
Analgesics and Anesthetics	0.4	0.1	0.0	0.3	13	9	0	4	33	111	36	1,281,182	324,739	23.2	3,294,279
Neuromuscular Agents	0.6	0.3	0.0	0.3	42	34	1	7	71	125	44	569,351	91,462	6.5	970,951
Nutritional Products	0.3	0.1	0.1	0.2	5	1	1	3	15	18	13	248,276	86,112	6.2	778,025
Hematological Agents	0.5	0.2	0.1	0.2	146	135	2	10	285	592	29	88,198	16,593	1.2	172,048
Topical Products	0.2	0.1	0.0	0.1	8	6	0	2	36	56	50	930,912	381,218	27.3	3,966,548
Miscellaneous Products	0.2	0.1	0.0	0.0	24	20	1	2	138	164	272	35,177	19,347	1.4	205,345
Unknown Therapeutic Category	0.1	0.0	0.0	0.0	3	0	0	0	24	0	0	126,275	89,568	6.4	950,832
<b>TOTAL NO. OF RX AND RX \$</b>	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	11,271,971	n.a.	n.a.	n.a.

Source: Data for this table are from the MAX 2003 file for Georgia, released by CMS in 04/2007. This table was produced on 11/01/2007.

- a. Table ND.6 includes the beneficiaries represented by Cell K of Table 1. A beneficiary who used drugs from two or more categories was counted as a user for each category. Therefore, the sum of users across categories may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
  - b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
  - c. For information about these therapeutic categories, see Wolters Kluwer Health, <http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).
  - d. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. In Georgia, 0.9 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined. For information about this classification method, see Wolters Kluwer Health, <http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).
  - e. A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2003.
- Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; CNS = Central Nervous System; MAX = Medicaid Analytic Extract; n.a. = not applicable; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.7  
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP<sup>a, b, c</sup>  
 NONDUAL BENEFICIARIES, GEORGIA, 2003

Top 10 Drug Groups	Users			Among Users		
	Total Medicaid Rx \$	Number of Users	As a Percentage of All Beneficiaries	Number of Benefit Months	Number of Rx per Benefit Month	Rx \$ per Benefit Month
ANTIPSYCHOTICS	\$61,408,081	55,164	3.9 %	613,371	0.5	\$197
ANTIASTHMATIC	48,533,680	298,829	21.4	3,188,697	0.2	61
ANTICONVULSANT	33,781,582	54,908	3.9	600,860	0.6	95
ANTIDEPRESSANTS	33,066,662	122,800	8.8	1,285,856	0.4	61
STIMULANTS/ANTI-OBESITY/ANOREXIANTS	25,289,995	66,448	4.8	734,287	0.5	74
ANTIVIRAL	24,831,381	31,040	2.2	329,141	0.2	305
DERMATOLOGICAL	23,616,705	373,669	26.7	3,967,089	0.2	39
ANALGESICS - Narcotic	20,762,395	317,854	22.8	3,248,695	0.2	27
PASSIVE IMMUNIZING AGENTS	20,617,450	3,138	0.2	28,407	0.5	1,341
ANTI-DIABETIC	16,941,134	42,353	3.0	453,602	0.6	61
<b>Total</b>	<b>308,849,065</b>	<b>1,366,203</b>		<b>14,450,005</b>	<b>n.a.</b>	<b>n.a.</b>

Source: Data for this table are from the MAX 2003 file for Georgia, released by CMS in 04/2007. This table was produced on 11/01/2007.

a. Table ND.7 includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2003. A beneficiary who used drugs from two or more groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2003. For information about these drug groups, see Wolters Kluwer Health, <http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad77847b6615> (October 26, 2007).

Bene Mo(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.7A  
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS COMBINED  
 AND FIRST AND SECOND GROUPS SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE<sup>a, b, c</sup>  
 NONDUAL BENEFICIARIES, GEORGIA, 2003

Beneficiary Characteristics	All Top 10 Drug Groups					ANTI-PSYCHOTICS					ANTI-ASTHMATIC						
	Number of Rx	Rx \$	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Number of Rx per Benefit Month	Mean Benefit per Rx \$ per Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Number of Rx per Benefit Month	Mean Benefit per Rx \$ per Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Number of Rx per Benefit Month	Mean Benefit per Rx \$ per Month
<b>All</b>	<b>4,097,302</b>	<b>\$308,849,065</b>	<b>55,164</b>	<b>3.9 %</b>	<b>613,371</b>	<b>0.5</b>	<b>\$100</b>	<b>298,829</b>	<b>21.4 %</b>	<b>3,188,697</b>	<b>0.2</b>	<b>\$15</b>					
<b>Female</b>	2,470,931	171,260,783	30,051	3.7	331,591	0.5	92	153,743	18.8	1,634,677	0.3	15					
<b>Disabled</b>	1,096,059	94,039,191	18,575	24.0	213,758	0.6	112	32,239	41.7	370,577	0.4	25					
5 and younger	18,519	3,102,751	81	1.8	931	0.4	70	2,520	56.9	28,626	0.3	22					
6-14	56,234	5,147,167	1,025	12.9	11,862	0.5	87	2,838	35.7	33,090	0.3	21					
15-20	39,805	3,993,136	1,026	18.5	11,947	0.5	98	1,268	22.8	14,800	0.3	18					
21-44	327,385	32,032,111	7,701	32.5	88,351	0.5	111	7,671	32.4	88,534	0.3	20					
45-64	633,060	48,443,457	8,503	24.8	97,951	0.6	119	17,314	50.5	198,380	0.5	29					
65-74	19,218	1,224,662	214	16.5	2,442	0.6	110	587	45.2	6,680	0.5	29					
75-84	1,714	92,548	24	12.8	262	0.5	78	36	19.3	407	0.3	19					
85 and older	124	3,359	1	3.7	12	1.1	48	5	18.5	60	0.2	5					
<b>Other Eligibles</b>	1,374,872	77,221,592	11,476	1.6	117,833	0.4	57	121,504	16.4	1,264,100	0.2	12					
5 and younger	279,115	19,128,211	201	0.1	2,282	0.3	46	55,276	25.1	582,140	0.2	12					
6-14	280,799	17,206,685	2,566	1.4	28,658	0.4	68	30,936	16.3	337,382	0.2	13					
15-20	163,418	8,406,854	1,950	1.9	20,815	0.4	56	10,939	10.9	112,790	0.2	11					
21-44	558,280	26,898,378	5,653	2.6	55,268	0.3	49	21,547	10.0	204,038	0.2	12					
45-64	68,008	4,092,064	648	6.2	6,214	0.3	54	2,198	20.9	21,395	0.3	19					
65-74	10,220	629,713	143	13.1	1,576	0.6	109	226	20.7	2,466	0.4	24					
75-84	9,793	569,763	164	17.2	1,628	0.6	88	246	25.8	2,559	0.4	24					
85 and older	5,239	289,924	151	25.6	1,392	0.6	72	136	23.1	1,330	0.4	17					
<b>Male</b>	1,626,356	137,588,076	25,113	4.3	281,780	0.5	109	145,086	25.0	1,554,020	0.2	15					
<b>Disabled</b>	695,151	72,585,157	15,990	21.7	182,998	0.6	126	21,872	29.7	247,849	0.4	24					
5 and younger	30,266	4,238,281	249	3.9	2,811	0.4	67	4,223	66.1	47,989	0.3	22					
6-14	129,989	11,888,480	3,353	21.9	38,819	0.5	96	5,608	36.6	65,489	0.3	19					
15-20	62,223	6,394,714	2,110	24.1	24,262	0.5	109	1,751	20.0	20,480	0.3	19					
21-44	199,514	25,497,189	6,385	32.0	73,285	0.6	145	2,710	13.6	30,506	0.4	20					
45-64	267,597	24,245,387	3,823	16.9	43,019	0.6	134	7,380	32.6	81,140	0.5	31					
65-74	4,827	280,636	57	11.8	660	0.6	84	185	38.3	2,073	0.5	34					
75-84	726	40,104	13	16.0	142	0.7	115	15	18.5	172	0.6	31					
85 and older	9	366	0	0.0	0	0.0	0	0	0.0	0	0.0	0					
<b>Other Eligibles</b>	931,205	65,002,919	9,123	1.8	98,782	0.5	78	123,214	24.3	1,306,171	0.2	14					
5 and younger	327,585	23,921,117	528	0.2	5,917	0.4	53	72,861	32.2	764,127	0.2	13					
6-14	417,882	28,706,649	5,671	3.0	63,180	0.5	78	40,789	21.4	443,885	0.2	14					
15-20	108,479	7,684,847	2,064	3.1	21,724	0.5	87	7,397	11.1	78,465	0.2	12					
21-44	50,314	2,848,813	554	3.1	4,946	0.3	64	1,275	7.0	11,019	0.3	16					
45-64	15,638	1,159,905	128	4.2	1,158	0.4	75	525	17.4	4,761	0.3	21					
65-74	4,500	296,281	67	11.1	731	0.6	108	153	25.3	1,695	0.4	20					
75-84	4,621	272,282	70	13.6	698	0.7	116	150	29.2	1,570	0.5	26					
85 and older	2,186	113,025	41	17.6	428	0.7	87	64	27.5	649	0.6	21					
<b>Unknown</b>	15	206	0	0.0	0	0.0	0	0	0.0	0	0.0	0					

Source: Data for this table are from the MAX 2003 file for Georgia, released by CMS in 04/2007. This table was produced on 11/01/2007.

a. Table ND.7A includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2003. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2003. For information about these drug groups, see Wolters Kluwer Health, <http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.7B

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR THIRD TO FIFTH TOP DRUG GROUPS SEPARATELY,  
BY SEX, BASIS OF ELIGIBILITY, AND AGE<sup>a,b,c</sup>  
NONDUAL BENEFICIARIES, GEORGIA, 2003

Beneficiary Characteristics	ANTICONVULSANT					ANTIDEPRESSANTS					STIMULANTS/ANTI-OBESITY/ANOREXIANTS				
	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean of Rx per Benefit Month	Mean Rx \$ per Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean of Rx per Benefit Month	Mean Rx \$ per Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean of Rx per Benefit Month	Mean Rx \$ per Month
<b>All</b>	<b>54,908</b>	<b>3.9 %</b>	<b>600,860</b>	<b>0.6</b>	<b>\$56</b>	<b>122,800</b>	<b>8.8 %</b>	<b>1,285,856</b>	<b>0.4</b>	<b>\$26</b>	<b>66,448</b>	<b>4.8 %</b>	<b>734,287</b>	<b>0.5</b>	<b>\$34</b>
<b>Female</b>	33,545	4.1	364,308	0.6	54	90,074	11.0	931,735	0.4	26	19,467	2.4	215,280	0.5	35
<b>Disabled</b>	19,811	25.6	226,784	0.7	64	35,364	45.7	403,742	0.5	31	3,732	4.8	43,187	0.5	40
5 and younger	505	11.4	5,748	0.7	85	41	0.9	486	0.3	10	136	3.1	1,535	0.3	26
6-14	1,553	19.6	17,995	0.8	82	1,023	12.9	11,779	0.4	23	2,057	25.9	23,885	0.5	35
15-20	1,153	20.8	13,244	0.8	89	1,361	24.5	15,804	0.4	27	615	11.1	7,177	0.5	37
21-44	7,266	30.7	83,416	0.7	69	12,623	53.3	144,217	0.5	30	482	2.0	5,503	0.4	50
45-64	9,106	26.6	103,801	0.6	54	19,813	57.8	225,716	0.5	32	437	1.3	5,027	0.5	60
65-74	204	15.7	2,326	0.6	40	449	34.5	5,131	0.6	30	5	0.4	60	0.4	18
75-84	22	11.8	230	0.6	53	53	28.3	602	0.6	29	0	0.0	0	0.0	0
85 and older	2	7.4	24	0.4	18	1	3.7	7	0.6	28	0	0.0	0	0.0	0
<b>Other Eligibles</b>	13,734	1.9	137,524	0.4	38	54,710	7.4	527,993	0.3	22	15,735	2.1	172,093	0.4	33
5 and younger	601	0.3	6,477	0.4	45	230	0.1	2,582	0.2	9	936	0.4	10,420	0.3	22
6-14	1,897	1.0	20,899	0.5	48	5,411	2.8	59,991	0.4	20	11,915	6.3	131,403	0.5	33
15-20	1,745	1.7	18,219	0.5	49	8,258	8.2	84,374	0.3	20	1,788	1.8	19,447	0.4	36
21-44	8,207	3.8	78,959	0.4	33	36,284	16.9	336,851	0.3	21	984	0.5	9,674	0.3	44
45-64	972	9.2	9,664	0.4	35	3,807	36.2	36,672	0.4	28	103	1.0	1,051	0.4	53
65-74	141	12.9	1,560	0.7	42	241	22.1	2,683	0.6	31	0	0.0	0	0.0	0
75-84	119	12.5	1,231	0.8	37	267	28.0	2,756	0.6	33	5	0.5	52	0.4	44
85 and older	52	8.8	515	0.7	28	212	36.0	2,084	0.6	36	4	0.7	46	0.3	19
<b>Male</b>	21,363	3.7	236,552	0.6	59	32,726	5.6	354,121	0.4	26	46,981	8.1	519,007	0.5	34
<b>Disabled</b>	14,833	20.1	168,259	0.7	66	16,862	22.9	189,693	0.5	29	10,035	13.6	116,175	0.5	37
5 and younger	766	12.0	8,671	0.6	63	108	1.7	1,221	0.4	10	525	8.2	5,972	0.3	22
6-14	2,680	17.5	30,979	0.7	66	2,608	17.0	30,079	0.5	24	7,219	47.1	83,582	0.5	37
15-20	1,726	19.7	19,800	0.7	73	1,784	20.4	20,626	0.5	28	1,772	20.2	20,646	0.5	37
21-44	5,133	25.8	58,353	0.8	79	5,564	27.9	62,381	0.5	32	365	1.8	4,244	0.5	48
45-64	4,459	19.7	49,677	0.6	51	6,704	29.6	74,385	0.5	30	152	0.7	1,707	0.5	56
65-74	61	12.6	699	0.6	30	79	16.4	858	0.6	25	1	0.2	12	0.2	22
75-84	8	9.9	80	0.8	23	15	18.5	143	0.6	28	1	1.2	12	0.3	10
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
<b>Other Eligibles</b>	6,530	1.3	68,293	0.5	41	15,864	3.1	164,428	0.4	22	36,946	7.3	402,832	0.5	34
5 and younger	911	0.4	10,015	0.4	39	387	0.2	4,344	0.3	11	2,585	1.1	28,619	0.3	22
6-14	2,849	1.5	31,470	0.5	41	7,805	4.1	86,365	0.4	22	30,190	15.8	329,676	0.5	34
15-20	1,220	1.8	12,803	0.5	45	3,966	5.9	40,936	0.4	24	3,994	6.0	42,969	0.5	38
21-44	1,087	6.0	9,518	0.4	37	2,716	15.0	23,508	0.3	23	142	0.8	1,244	0.3	33
45-64	305	10.1	2,776	0.4	39	709	23.5	6,257	0.4	24	30	1.0	271	0.3	45
65-74	70	11.6	778	0.6	40	108	17.9	1,220	0.6	31	2	0.3	21	0.3	49
75-84	61	11.9	632	0.8	47	117	22.8	1,236	0.6	31	2	0.4	24	0.6	25
85 and older	27	11.6	301	0.5	26	56	24.0	562	0.7	38	1	0.4	8	0.5	4
<b>Unknown</b>	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Table ND7B

Nondual Beneficiaries

Source: Data for this table are from the MAX 2003 file for Georgia, released by CMS in 04/2007. This table was produced on 11/01/2007.

a. Table ND.7B includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2003. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2003. For information about these drug groups, see Wolters Kluwer Health, <http://www.medispain.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.



TABLE ND.7C  
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR SIXTH TO EIGHTH TOP DRUG GROUPS SEPARATELY,  
 BY SEX, BASIS OF ELIGIBILITY, AND AGE<sup>a,b,c</sup>  
 NONDUAL BENEFICIARIES, GEORGIA, 2003

Beneficiary Characteristics	ANTIVIRAL					DERMATOLOGICAL					ANALGESICS - Narcotic				
	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean Rx per Benefit Month	Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean Rx per Benefit Month	Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean Rx per Benefit Month	Mean Rx \$ per Benefit Month
<b>All</b>	<b>31,040</b>	<b>2.2%</b>	<b>329,141</b>	<b>0.2</b>	<b>\$75</b>	<b>373,669</b>	<b>26.7%</b>	<b>3,967,089</b>	<b>0.2</b>	<b>\$6</b>	<b>317,854</b>	<b>22.8%</b>	<b>3,248,695</b>	<b>0.2</b>	<b>\$6</b>
<b>Female</b>	19,312	2.4	202,225	0.2	68	219,940	26.9	2,329,117	0.2	6	243,505	29.8	2,458,878	0.2	6
<b>Disabled</b>	5,233	6.8	59,038	0.4	146	26,582	34.3	309,951	0.2	8	57,916	74.8	666,507	0.3	13
5 and younger	122	2.8	1,427	0.2	22	1,938	43.7	22,182	0.1	5	397	9.0	4,612	0.1	1
6-14	330	4.2	3,849	0.4	97	2,816	35.5	33,041	0.1	6	1,115	14.0	12,998	0.1	2
15-20	204	3.7	2,383	0.2	52	1,897	34.1	22,312	0.2	7	1,957	35.2	22,885	0.2	3
21-44	2,566	10.8	28,580	0.4	158	7,773	32.8	90,915	0.2	7	20,636	87.2	238,255	0.3	12
45-64	1,969	5.7	22,329	0.4	158	11,707	34.1	136,282	0.2	9	32,773	95.6	375,899	0.4	15
65-74	38	2.9	422	0.3	95	395	30.4	4,576	0.2	10	927	71.3	10,599	0.3	12
75-84	3	1.6	36	0.1	5	49	26.2	570	0.2	8	99	52.9	1,125	0.3	9
85 and older	1	3.7	12	0.1	6	7	25.9	73	0.2	5	12	44.4	134	0.5	8
<b>Other Eligibles</b>	14,079	1.9	143,187	0.2	36	193,358	26.1	2,019,166	0.2	6	185,589	25.1	1,792,371	0.2	3
5 and younger	2,918	1.3	31,652	0.1	7	92,412	41.9	961,430	0.1	5	7,104	3.2	78,661	0.1	1
6-14	2,662	1.4	29,209	0.1	18	46,789	24.6	515,978	0.1	6	13,825	7.3	151,451	0.1	1
15-20	2,246	2.2	23,117	0.1	18	20,660	20.5	217,653	0.2	8	31,558	31.3	313,324	0.1	1
21-44	5,900	2.7	55,615	0.2	61	30,474	14.2	292,696	0.2	7	124,328	57.8	1,161,666	0.2	4
45-64	295	2.8	2,952	0.3	183	2,115	20.1	21,459	0.2	8	7,649	72.7	74,950	0.3	8
65-74	26	2.4	270	0.3	44	354	32.5	3,996	0.3	14	495	45.4	5,346	0.3	9
75-84	10	1.0	120	0.3	130	311	32.6	3,377	0.2	11	433	45.4	4,723	0.4	11
85 and older	22	3.7	252	0.1	8	243	41.3	2,577	0.2	7	217	36.8	2,250	0.4	12
<b>Male</b>	11,728	2.0	126,916	0.3	88	153,724	26.5	1,637,922	0.2	6	74,346	12.8	789,781	0.2	9
<b>Disabled</b>	4,766	6.5	51,752	0.5	187	18,165	24.7	209,436	0.2	7	28,314	38.5	315,893	0.3	17
5 and younger	155	2.4	1,786	0.2	19	2,487	38.9	28,315	0.1	5	610	9.6	7,017	0.1	1
6-14	383	2.5	4,403	0.3	72	4,239	27.7	49,892	0.1	5	1,805	11.8	21,073	0.1	2
15-20	192	2.2	2,225	0.2	37	2,271	25.9	26,520	0.2	8	2,003	22.9	23,285	0.2	3
21-44	2,252	11.3	23,484	0.5	194	4,157	20.9	47,616	0.2	8	9,122	45.8	101,871	0.3	16
45-64	1,780	7.9	19,806	0.5	237	4,874	21.5	55,490	0.2	10	14,504	64.0	159,602	0.4	22
65-74	4	0.8	48	0.3	216	118	24.4	1,388	0.2	8	230	47.6	2,618	0.3	9
75-84	0	0.0	0	0.0	0	19	23.5	215	0.2	6	38	46.9	403	0.4	4
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	2	28.6	24	0.4	15
<b>Other Eligibles</b>	6,962	1.4	75,164	0.1	19	135,559	26.8	1,428,486	0.1	6	46,032	9.1	473,888	0.2	3
5 and younger	3,073	1.4	33,579	0.1	6	86,988	38.4	898,671	0.1	5	9,663	4.3	106,726	0.1	1
6-14	2,505	1.3	27,585	0.1	14	35,242	18.5	389,616	0.1	6	13,972	7.3	153,918	0.1	1
15-20	1,008	1.5	10,640	0.1	19	11,206	16.8	120,145	0.2	9	10,757	16.1	112,247	0.1	1
21-44	280	1.5	2,421	0.3	143	1,339	7.4	12,007	0.2	8	9,301	51.4	79,337	0.3	10
45-64	79	2.6	743	0.5	338	350	11.6	3,266	0.2	9	1,844	61.0	16,401	0.4	17
65-74	10	1.7	114	0.3	178	171	28.3	1,944	0.2	9	223	36.9	2,426	0.3	11
75-84	7	1.4	82	0.2	24	178	34.7	1,948	0.2	12	185	36.1	1,961	0.3	8
85 and older	0	0.0	0	0.0	0	85	36.5	889	0.3	8	87	37.3	872	0.4	10
<b>Unknown</b>	0	0.0	0	0.0	0	5	21.7	50	0.1	1	3	13.0	36	0.3	5

Table ND7C

Nondual Beneficiaries

Source: Data for this table are from the MAX 2003 file for Georgia, released by CMS in 04/2007. This table was produced on 11/01/2007.

a. Table ND.7C includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2003. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2003. For information about these drug groups, see Wolters Kluwer Health, <http://www.medispain.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

Bene Mo(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.7D  
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR NINTH AND TENTH TOP DRUG GROUPS  
 SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE<sup>a, b, c</sup>  
 NONDUAL BENEFICIARIES, GEORGIA, 2003

Beneficiary Characteristics	PASSIVE IMMUNIZING AGENTS					ANTI-DIABETIC						
	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean of Rx Benefit per Month	Mean of Rx Benefit per Rx \$ per Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean of Rx Benefit per Month	Mean of Rx Benefit per Rx \$ per Month	Number of Beneficiaries	Number of Benefit Months
<b>All</b>	<b>3,138</b>	<b>0.2 %</b>	<b>28,407</b>	<b>0.5</b>	<b>\$726</b>	<b>42,353</b>	<b>3.0 %</b>	<b>453,602</b>	<b>0.6</b>	<b>\$37</b>	<b>1,397,022</b>	<b>12,578,532</b>
<b>Female</b>	1,552	0.2	13,892	0.5	721	32,199	3.9	345,637	0.6	37	816,881	7,196,720
<b>Disabled</b>	306	0.4	3,159	0.6	1,023	20,436	26.4	233,701	0.6	40	77,397	839,537
5 and younger	265	6.0	2,679	0.5	645	24	0.5	271	0.7	50	4,432	46,190
6-14	13	0.2	156	0.9	1,199	100	1.3	1,174	0.6	47	7,941	89,412
15-20	8	0.1	90	0.7	3,077	172	3.1	2,008	0.6	32	5,556	62,141
21-44	13	0.1	156	0.8	4,263	3,890	16.4	44,896	0.6	36	23,669	259,192
45-64	7	0.0	78	1.2	4,792	15,497	45.2	176,784	0.7	41	34,285	365,796
65-74	0	0.0	0	0.0	0	685	52.7	7,820	0.7	40	1,300	14,500
75-84	0	0.0	0	0.0	0	64	34.2	717	0.7	28	187	2,043
85 and older	0	0.0	0	0.0	0	4	14.8	31	0.4	12	27	263
<b>Other Eligibles</b>	1,246	0.2	10,733	0.5	633	11,763	1.6	111,936	0.5	30	739,484	6,357,183
5 and younger	1,174	0.5	10,092	0.5	652	86	0.0	978	0.7	42	220,568	1,971,950
6-14	4	0.0	44	0.4	1,067	597	0.3	6,473	0.7	44	189,991	1,832,161
15-20	13	0.0	126	0.2	129	872	0.9	8,757	0.6	36	100,663	857,810
21-44	55	0.0	471	0.2	304	7,401	3.4	68,411	0.5	27	215,112	1,585,819
45-64	0	0.0	0	0.0	0	1,961	18.6	18,356	0.6	33	10,517	84,999
65-74	0	0.0	0	0.0	0	376	34.5	3,992	0.7	34	1,090	9,772
75-84	0	0.0	0	0.0	0	347	36.4	3,775	0.7	32	954	9,285
85 and older	0	0.0	0	0.0	0	123	20.9	1,194	0.7	24	589	5,387
<b>Male</b>	1,586	0.3	14,515	0.5	730	10,154	1.8	107,965	0.6	39	580,118	5,381,680
<b>Disabled</b>	329	0.4	3,433	0.5	844	7,650	10.4	84,730	0.6	39	73,627	776,612
5 and younger	303	4.7	3,132	0.5	668	9	0.1	98	0.9	74	6,387	66,481
6-14	16	0.1	183	1.2	2,075	104	0.7	1,172	0.7	43	15,311	171,399
15-20	6	0.1	70	0.6	1,893	133	1.5	1,524	0.6	36	8,755	97,637
21-44	4	0.0	48	0.8	6,101	1,522	7.6	17,152	0.6	38	19,931	209,567
45-64	0	0.0	0	0.0	0	5,702	25.1	62,812	0.6	39	22,672	225,155
65-74	0	0.0	0	0.0	0	158	32.7	1,730	0.7	39	483	5,388
75-84	0	0.0	0	0.0	0	22	27.2	242	0.8	40	81	903
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	7	82
<b>Other Eligibles</b>	1,257	0.2	11,082	0.6	695	2,504	0.5	23,235	0.6	39	506,491	4,605,068
5 and younger	1,251	0.6	11,010	0.5	687	89	0.0	956	0.6	36	226,340	2,023,134
6-14	4	0.0	48	0.9	2,109	451	0.2	4,659	0.7	46	191,002	1,838,040
15-20	2	0.0	24	0.5	1,475	368	0.6	3,776	0.7	53	66,668	596,754
21-44	0	0.0	0	0.0	0	743	4.1	6,060	0.6	36	18,108	113,911
45-64	0	0.0	0	0.0	0	528	17.5	4,372	0.6	35	3,023	20,843
65-74	0	0.0	0	0.0	0	149	24.7	1,511	0.7	31	604	5,286
75-84	0	0.0	0	0.0	0	130	25.3	1,399	0.7	29	513	4,915
85 and older	0	0.0	0	0.0	0	46	19.7	502	0.8	33	233	2,185
<b>Unknown</b>	0	0.0	0	0.0	0	0	0.0	0	0.0	0	23	132

Source: Data for this table are from the MAX 2003 file for Georgia, released by CMS in 04/2007. This table was produced on 11/01/2007.

- a. Table ND.7D includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2003. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2003. For information about these drug groups, see Wolters Kluwer Health, <http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy; \$ = Medicaid reimbursement.

TABLE ND.8  
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS,  
 BY BENEFICIARY CHARACTERISTIC<sup>a, b</sup>  
 NONDUAL BENEFICIARIES, GEORGIA, 2003

Beneficiary Characteristics	Rx \$ per Benefit Month	Number of Rx per Benefit Month	Benefit Month	Number of All-Year Nursing Facility Residents	Benefit Months Among All-Year Nursing Facility Residents
<b>All</b>	<b>\$383</b>	<b>6.6</b>		<b>2,021</b>	<b>21,124</b>
<b>Age</b>					
0-64	422	6.7		1,304	13,848
65-74	393	7.0		218	2,381
75-84	318	6.4		235	2,289
85 and older	228	5.4		264	2,606
Unknown	0	0.0		0	0
<b>Gender</b>					
Female	391	6.9		1,195	12,406
Male	373	6.2		826	8,718
Unknown	0	0.0		0	0
<b>Race</b>					
White	392	6.9		970	9,952
African American	371	6.2		889	9,412
Other/unknown	399	6.9		162	1,760
<b>Basis of Eligibility<sup>c</sup></b>					
Aged	305	6.1		677	6,879
Disabled	421	6.8		1,344	14,245
Adults	0	0.0		0	0
Children	0	0.0		0	0
Unknown	0	0.0		0	0

Source: Data for this table are from the MAX 2003 file for Georgia, released by CMS in 04/2007. This table was produced on 11/01/2007.

a. Table ND.8 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their 2003 Medicaid enrollment. A total of 1,440 beneficiaries who were in nursing facilities for part of their enrollment and their 14,358 benefit months were excluded from the analysis. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy; \$ = Medicaid reimbursement.

TABLE ND.9

**MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS,  
BY BRAND STATUS AND THERAPEUTIC CATEGORY<sup>a, b, c, d, e</sup>  
NONDUAL BENEFICIARIES, GEORGIA, 2003**

Therapeutic Category	Number of Rx per Benefit Month Among Users			\$ per Benefit Month Among Users			\$ per Rx			Users						
	Total	Patented Brand-Name	Off-Patent Brand-Name	Generic	Total	Patented Brand-Name	Off-Patent Brand-Name	Generic	Total	Patented Brand-Name	Off-Patent Brand-Name	Generic	Total Rx \$	Number of Users	Percentage of All-Year Nursing Facility Residents	Number of Benefit Months
Anti-infective Agents	0.4	0.2	0.0	0.2	\$34	\$29	\$1	\$5	\$86	\$135	\$88	\$26	\$495,632	1,332	65.9 %	14,436
Biologicals	0.1	0.1	0.0	0.0	10	10	0	0	123	123	0	0	123	1	0.0	12
Antineoplastic Agents	0.5	0.1	0.0	0.4	117	76	4	38	235	665	222	102	157,981	131	6.5	1,350
Endocrine/Metabolic Drugs	1.2	0.7	0.1	0.4	56	48	2	6	47	71	18	16	528,285	861	42.6	9,385
Cardiovascular Agents	2.0	0.6	0.1	1.3	64	40	2	22	32	64	25	17	928,260	1,370	67.8	14,484
Respiratory Agents	0.7	0.2	0.0	0.4	31	21	0	9	44	89	40	21	290,148	879	43.5	9,503
Gastrointestinal Agents	1.0	0.2	0.0	0.8	35	19	0	15	34	110	47	18	390,982	1,052	52.1	11,206
Genitourinary Agents	0.6	0.5	0.0	0.1	38	35	0	3	63	72	26	23	144,426	343	17.0	3,836
CNS Drugs	1.7	1.0	0.1	0.7	167	148	3	15	99	156	67	22	2,647,973	1,491	73.8	15,893
Stimulants/Anti-obesity/Anorexia	0.8	0.4	0.0	0.4	63	57	0	6	81	134	0	17	14,656	22	1.1	233
Miscellaneous Psychological/Neurological Agents	0.8	0.8	0.0	0.0	113	112	0	0	141	142	0	50	235,191	198	9.8	2,083
Analgesics and Anesthetics	1.0	0.4	0.0	0.6	44	35	1	8	44	93	24	14	519,543	1,086	53.7	11,728
Neuromuscular Agents	1.4	0.5	0.2	0.7	86	57	7	22	63	115	36	33	971,391	1,033	51.1	11,280
Nutritional Products	0.7	0.0	0.0	0.7	13	0	1	11	17	19	19	17	70,875	540	26.7	5,662
Hematological Agents	1.1	0.4	0.3	0.3	88	77	5	5	82	186	16	16	441,326	484	23.9	5,040
Topical Products	0.5	0.2	0.0	0.3	20	13	2	5	37	54	47	20	249,902	1,119	55.4	12,398
Miscellaneous Products	0.2	0.0	0.0	0.2	8	1	0	7	33	51	0	31	5,671	71	3.5	712
Unknown Therapeutic Category	0.2	0.0	0.0	0.0	9	0	0	0	46	0	0	0	4,334	43	2.1	500
<b>TOTAL NO. OF RX AND RX \$</b>	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	8,096,699	n.a.	n.a.	n.a.

Source: Data for this table are from the MAX 2003 file for Georgia, released by CMS in 04/2007. This table was produced on 11/01/2007.

a. Table ND.9 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2003. A total of 1,440 beneficiaries who were in nursing facilities for part of their enrollment and their 14,358 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2003. A beneficiary who used drugs from two or more categories was counted as a user for each category. Therefore, the sum of users across categories may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. For information about these therapeutic categories, see Wolters Kluwer Health, <http://www.medspan.com/marketing/ContentPage.aspx?contentid=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

e. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. For information about this classification method, see Wolters Kluwer Health, <http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

In Georgia, 0.9 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined.

Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; CNS = Central Nervous System; MAX = Medicaid Analytic Extract; n.a. = not applicable; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.10  
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS,  
 BY TOP-10 DRUG GROUP<sup>a, b, c, d</sup>  
 NONDUAL BENEFICIARIES, GEORGIA, 2003

	Users				Among Users		
	Total Medicaid Rx \$	Number of Users	As a Percentage of All-Year Nursing Facility Residents	Number of Benefit Months	Number of Rx per Benefit Month	\$ per Rx	Rx \$ per Benefit Month
Top 10 Drug Groups in Nursing Facilities	\$1,842,517	1,129	55.9 %	12,447	0.8	\$193	\$148
ANTIPTYCHOTICS							
ANTICONVULSANT	809,762	1,098	54.3	12,219	1.0	68	66
ANTIDEPRESSANTS	670,670	1,205	59.6	13,066	0.8	64	51
ANTIIDIABETIC	450,324	940	46.5	10,317	0.9	48	44
ULCER DRUGS	313,440	1,071	53.0	11,639	0.7	37	27
ANTIHYPERTENSIVE	300,927	982	48.6	10,562	0.8	36	28
ANALGESICS - Narcotic	251,248	1,117	55.3	12,103	0.6	34	21
MISC PSYCHOTHERAPEUTIC AND NEUROLOGICAL							
CALCIUM BLOCKERS	235,191	194	9.6	2,050	0.8	141	115
MISC. HEMATOLOGICAL	207,857	480	23.8	5,034	0.9	48	41
	200,501	234	11.6	2,512	0.8	105	80
Total	5,282,437	8,450		91,949	n.a.	n.a.	n.a.

Source: Data for this table are from the MAX 2003 file for Georgia, released by CMS in 04/2007. This table was produced on 11/01/2007.

a. Table ND.10 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2003. A total of 1,440 beneficiaries who were in nursing facilities for part of their enrollment and their 14,358 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2003. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2003 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, <http://www.medspan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.



TABLE ND.10A

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR TOP 10 DRUG GROUPS COMBINED AND FIRST AND SECOND TOP DRUG GROUPS SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE<sup>a, b, c, d</sup> NONDUAL BENEFICIARIES, GEORGIA, 2003

Beneficiary Characteristics	All Top 10 Drug Groups					ANTIPSYCHOTICS					ANTICONVULSANT					
	Number of Rx	Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx
<b>All</b>	<b>73,531</b>	<b>\$5,282,437</b>	<b>1,129</b>	<b>55.9 %</b>	<b>12,447</b>	<b>0.8</b>	<b>\$148</b>	<b>1,098</b>	<b>54.3 %</b>	<b>12,219</b>	<b>1.0</b>	<b>\$66</b>				
<b>Female</b>	45,216	3,180,503	684	57.2	7,464	0.7	140	629	52.6	6,957	1.0	66				
<b>Disabled</b>	30,099	2,224,906	451	62.9	5,031	0.8	154	487	67.9	5,407	1.0	73				
64 or younger	29,060	2,161,356	438	63.5	4,895	0.8	156	479	69.4	5,320	1.0	72				
65-74	976	59,673	12	52.2	131	0.7	101	8	34.8	87	0.9	78				
75-84	60	3,767	1	33.3	5	0.4	106	0	0.0	0	0.0	0				
85 and older	3	110	0	0.0	0	0.0	0	0	0.0	0	0.0	0				
<b>Other Eligibles</b>	15,117	955,597	233	48.7	2,433	0.7	109	142	29.7	1,550	0.9	43				
64 or younger	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0				
65-74	5,292	359,960	80	65.0	919	0.7	138	66	53.7	733	0.9	48				
75-84	5,240	338,140	82	52.2	829	0.7	106	51	32.5	538	0.9	43				
85 and older	4,585	257,497	71	35.9	685	0.6	75	25	12.6	279	0.8	29				
<b>Male</b>	28,315	2,101,934	445	53.9	4,983	0.8	161	469	56.8	5,262	1.0	67				
<b>Disabled</b>	22,380	1,716,513	345	55.0	3,912	0.8	169	408	65.1	4,576	1.0	69				
64 or younger	21,816	1,688,509	341	55.5	3,864	0.8	171	403	65.6	4,516	1.0	69				
65-74	564	28,004	4	30.8	48	0.6	68	5	38.5	60	1.0	51				
75-84	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0				
85 and older	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0				
<b>Other Eligibles</b>	5,935	385,421	100	50.3	1,071	0.8	129	61	30.7	686	0.8	51				
64 or younger	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0				
65-74	2,220	156,372	32	54.2	354	0.9	155	25	42.4	298	0.9	54				
75-84	2,119	132,630	38	50.7	395	0.9	138	22	29.3	220	0.9	57				
85 and older	1,596	96,419	30	46.2	322	0.7	90	14	21.5	168	0.6	36				
<b>Unknown</b>	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0				

Source: Data for this table are from the MAX 2003 file for Georgia, released by CMS in 04/2007. This table was produced on 11/01/2007.

- a. Table ND.10A includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2003. A total of 1,440 beneficiaries who were in nursing facilities for part of their enrollment and their 14,358 benefit months were excluded from the analysis.
- b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2003. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- d. The top 10 drug groups were determined based on total 2003 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, <http://www.medspan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).
- Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.10B  
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR THIRD TO FIFTH TOP DRUG GROUPS SEPARATELY  
 AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE<sup>a, b, c, d</sup>  
 NONDUAL BENEFICIARIES, GEORGIA, 2003

Beneficiary Characteristics	ANTIDEPRESSANTS				ANTI-DIABETIC				ULCER DRUGS						
	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$
<b>All</b>	<b>1,205</b>	<b>59.6 %</b>	<b>13,066</b>	<b>0.8</b>	<b>\$51</b>	<b>940</b>	<b>46.5 %</b>	<b>10,317</b>	<b>0.9</b>	<b>\$44</b>	<b>1,071</b>	<b>53.0 %</b>	<b>11,639</b>	<b>0.7</b>	<b>\$27</b>
<b>Female</b>	761	63.7	8,254	0.8	53	630	52.7	6,856	0.9	44	638	53.4	6,938	0.7	27
<b>Disabled</b>	491	68.5	5,388	0.8	57	424	59.1	4,654	1.0	47	394	55.0	4,303	0.7	28
64 or younger	472	68.4	5,198	0.8	57	401	58.1	4,440	1.0	46	377	54.6	4,128	0.7	28
65-74	17	73.9	166	0.8	59	20	87.0	189	1.3	72	16	69.6	163	0.7	31
75-84	2	66.7	24	0.8	37	2	66.7	24	0.7	32	1	33.3	12	0.3	6
85 and older	0	0.0	0	0.0	0	1	100.0	1	1.0	30	0	0.0	0	0.0	0
<b>Other Eligibles</b>	270	56.5	2,866	0.8	47	206	43.1	2,202	0.8	38	244	51.0	2,635	0.7	26
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
65-74	69	56.1	786	0.8	49	74	60.2	856	0.9	52	71	57.7	805	0.7	34
75-84	98	62.4	1,023	0.8	49	74	47.1	767	0.7	33	85	54.1	912	0.6	24
85 and older	103	52.0	1,057	0.7	45	58	29.3	579	0.8	26	88	44.4	918	0.7	21
<b>Male</b>	444	53.8	4,812	0.8	48	310	37.5	3,461	0.9	43	433	52.4	4,701	0.7	26
<b>Disabled</b>	329	52.5	3,578	0.8	50	249	39.7	2,785	0.9	44	347	55.3	3,776	0.7	27
64 or younger	322	52.4	3,494	0.8	51	241	39.3	2,689	0.9	44	340	55.4	3,692	0.7	27
65-74	7	53.8	84	0.9	32	8	61.5	96	0.8	50	7	53.8	84	0.7	28
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
<b>Other Eligibles</b>	115	57.8	1,234	0.7	41	61	30.7	676	0.9	37	86	43.2	925	0.7	23
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
65-74	40	67.8	456	0.7	46	24	40.7	267	0.9	38	24	40.7	273	0.7	26
75-84	41	54.7	429	0.7	36	25	33.3	299	1.0	38	38	50.7	381	0.8	23
85 and older	34	52.3	349	0.7	42	12	18.5	110	1.1	33	24	36.9	271	0.7	19
<b>Unknown</b>	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Source: Data for this table are from the MAX 2003 file for Georgia, released by CMS in 04/2007. This table was produced on 11/01/2007.

- a. Table ND.10B includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2003. A total of 1,440 beneficiaries who were in nursing facilities for part of their enrollment and their 14,358 benefit months were excluded from the analysis.
  - b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2003. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
  - c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
  - d. The top 10 drug groups were determined based on total 2003 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, <http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0ffed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).
- Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

Table ND10B

Nondual Beneficiaries

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR SIXTH TO EIGHTH TOP DRUG GROUPS SEPARATELY  
 AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE<sup>a, b, c, d</sup>  
 NONDUAL BENEFICIARIES, GEORGIA, 2003

Beneficiary Characteristics	ANTIHYPERTENSIVE				ANALGESICS - Narcotic				MISC PSYCHOTHERAPEUTIC AND NEUROLOGICAL						
	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$
<b>All</b>	<b>982</b>	<b>48.6 %</b>	<b>10,562</b>	<b>0.8</b>	<b>\$29</b>	<b>1,117</b>	<b>55.3 %</b>	<b>12,103</b>	<b>0.6</b>	<b>\$21</b>	<b>194</b>	<b>9.6 %</b>	<b>2,050</b>	<b>0.8</b>	<b>\$115</b>
<b>Female</b>															
<b>Disabled</b>	576	48.2	6,149	0.8	28	697	58.3	7,591	0.6	22	132	11.0	1,368	0.8	118
64 or younger	319	44.5	3,468	0.8	30	433	60.4	4,737	0.7	22	45	6.3	499	0.8	145
65-74	306	44.3	3,338	0.8	30	415	60.1	4,552	0.7	23	42	6.1	468	0.9	147
75-84	11	47.8	113	0.8	25	17	73.9	180	0.6	8	2	8.7	19	0.8	118
85 and older	2	66.7	17	0.5	5	1	33.3	5	0.2	2	1	33.3	12	0.8	119
<b>Other Eligibles</b>	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
64 or younger	257	53.8	2,681	0.8	26	264	55.2	2,854	0.6	23	87	18.2	869	0.8	103
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
75-84	74	60.2	867	0.8	31	90	73.2	1,001	0.7	23	8	6.5	87	0.7	85
85 and older	92	58.6	899	0.7	24	88	56.1	921	0.6	27	36	22.9	367	0.8	109
	91	46.0	915	0.7	22	86	43.4	932	0.5	18	43	21.7	415	0.8	101
<b>Male</b>															
<b>Disabled</b>	406	49.2	4,413	0.8	29	420	50.8	4,512	0.6	18	62	7.5	682	0.8	108
64 or younger	309	49.3	3,340	0.8	30	327	52.2	3,498	0.6	20	27	4.3	310	0.9	121
65-74	299	48.7	3,220	0.8	30	317	51.6	3,378	0.6	19	26	4.2	298	0.9	123
75-84	10	76.9	120	0.8	25	10	76.9	120	0.7	27	1	7.7	12	0.7	93
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
<b>Other Eligibles</b>	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
64 or younger	97	48.7	1,073	0.8	27	93	46.7	1,014	0.5	13	35	17.6	372	0.8	97
65-74	40	67.8	460	0.8	29	22	37.3	264	0.5	11	11	18.6	116	0.8	113
75-84	32	42.7	351	0.8	23	34	45.3	382	0.4	12	11	14.7	125	0.6	75
85 and older	25	38.5	262	0.7	29	37	56.9	368	0.5	16	13	20.0	131	0.8	105
<b>Unknown</b>	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Source: Data for this table are from the MAX 2003 file for Georgia, released by CMS in 04/2007. This table was produced on 11/01/2007.

- a. Table ND.10C includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2003. A total of 1,440 beneficiaries who were in nursing facilities for part of their enrollment and their 14,358 benefit months were excluded from the analysis.
  - b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2003. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
  - c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
  - d. The top 10 drug groups were determined based on total 2003 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, <http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).
- Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.10D  
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR NINTH AND TENTH TOP DRUG GROUPS  
 SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE<sup>a, b, c, d</sup>  
 NONDUAL BENEFICIARIES, GEORGIA, 2003

Beneficiary Characteristics	CALCIUM BLOCKERS				MISC. HEMATOLOGICAL				Benefit Months Among All-Nursing Facility Residents			
	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users		Mean Number of Rx	Mean Rx \$	
<b>All</b>	<b>480</b>	<b>23.8 %</b>	<b>5,034</b>	<b>0.9</b>	<b>\$41</b>	<b>234</b>	<b>11.6 %</b>	<b>2,512</b>	<b>0.8</b>	<b>\$80</b>	<b>2,021</b>	<b>21,124</b>
<b>Female</b>	302	25.3	3,128	0.9	42	139	11.6	1,478	0.8	79	1,195	12,406
<b>Disabled</b>	149	20.8	1,592	0.9	45	77	10.7	826	0.8	76	717	7,582
64 or younger	142	20.6	1,533	0.9	45	72	10.4	788	0.7	77	690	7,341
65-74	6	26.1	58	1.0	49	4	17.4	37	0.9	52	23	222
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	3	18
85 and older	1	100.0	1	1.0	46	1	100.0	1	1.0	34	1	1
<b>Other Eligibles</b>	153	32.0	1,536	0.9	38	62	13.0	652	0.8	84	478	4,824
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
65-74	41	33.3	467	0.8	40	16	13.0	176	0.8	71	123	1,361
75-84	52	33.1	498	0.9	38	28	17.8	290	0.9	87	157	1,531
85 and older	60	30.3	571	0.9	37	18	9.1	186	0.7	90	198	1,932
<b>Male</b>	178	21.5	1,906	0.9	41	95	11.5	1,034	0.8	81	826	8,718
<b>Disabled</b>	121	19.3	1,319	0.9	44	78	12.4	836	0.7	79	627	6,663
64 or younger	116	18.9	1,259	0.9	44	77	12.5	824	0.7	78	614	6,507
65-74	5	38.5	60	0.9	55	1	7.7	12	0.8	98	13	156
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
<b>Other Eligibles</b>	57	28.6	587	0.8	33	17	8.5	198	0.9	91	199	2,055
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
65-74	19	32.2	204	0.7	38	10	16.9	120	0.9	88	59	642
75-84	17	22.7	172	0.7	31	3	4.0	32	0.9	105	75	740
85 and older	21	32.3	211	0.9	31	4	6.2	46	0.8	90	65	673
<b>Unknown</b>	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0

Source: Data for this table are from the MAX 2003 file for Georgia, released by CMS in 04/2007. This table was produced on 11/01/2007.

- a. Table ND.10D includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2003. A total of 1,440 beneficiaries who were in nursing facilities for part of their enrollment and their 14,358 benefit months were excluded from the analysis.
- b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2003. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- d. The top 10 drug groups were determined based on total 2003 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, <http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).  
 Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.11  
 USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D  
 AMONG NONDUALS, BY BENEFICIARY CHARACTERISTIC<sup>a,b</sup>  
 GEORGIA, 2003

Beneficiary Characteristics	Number of Beneficiaries with at Least One Part D Excluded Rx	Percentage of Beneficiaries with at Least One Part D Excluded Rx	Number of Part D Excluded Rx per Beneficiary	Total Number Part D Excluded Rx	Rx \$ per Beneficiary	Total Part D Excluded Rx \$	\$ per Part D Excluded Rx	Part D Excluded Rx	
								All Nondual Rx \$	Beneficiaries
<b>All</b>	<b>467,766</b>	<b>33.5 %</b>	<b>0.9</b>	<b>1,275,231</b>	<b>\$18</b>	<b>\$25,389,962</b>	<b>\$20</b>	<b>4.3 %</b>	<b>1,397,022</b>
<b>Age</b>									
5 and younger	217,757	47.6	1.3	592,324	23	10,602,118	18	10.5	457,748
6-14	122,024	30.2	0.6	260,605	15	6,190,572	24	5.4	404,245
15-20	45,957	25.3	0.5	99,252	14	2,506,195	25	4.6	181,642
21-44	54,856	19.8	0.6	158,779	12	3,372,273	21	2.1	276,820
45-64	25,138	35.7	2.1	150,512	36	2,560,285	17	1.7	70,497
65-74	1,167	33.6	2.3	7,986	27	95,108	12	1.5	3,478
75-84	563	32.4	2.2	3,772	24	42,006	11	1.4	1,735
85 and older	304	35.5	2.3	2,001	25	21,405	11	1.7	856
Unknown	0	0.0	0.0	0	0	0	0	0.0	1
<b>Basis of Eligibility<sup>c</sup></b>									
Aged	1,852	31.1	1.6	9,802	19	115,666	12	1.3	5,963
Disabled	53,885	35.7	1.8	274,087	49	7,377,746	27	2.5	151,025
Adults	55,346	19.6	0.4	124,461	6	1,709,167	14	2.0	281,777
Children	356,683	37.2	0.9	866,881	17	16,187,383	19	8.1	958,257
Unknown	0	0.0	0.0	0	0	0	0	0.0	0
<b>Gender</b>									
Female	265,853	32.5	0.9	730,664	17	14,277,088	20	4.1	816,882
Male	201,912	34.8	0.9	544,562	19	11,112,827	20	4.5	580,118
Unknown	1	4.5	0.2	5	2	47	9	2.7	22
<b>Race</b>									
White	221,686	39.1	1.1	635,670	22	12,673,488	20	4.5	567,008
African American	201,690	28.7	0.7	500,863	14	9,542,807	19	4.1	703,422
Other/unknown	44,390	35.1	1.1	138,698	25	3,173,667	23	4.2	126,592
<b>Use of Nursing Facilities<sup>d</sup></b>									
Entire year	1,189	58.8	6.0	12,187	83	168,378	14	2.1	2,021
Part year	944	65.6	5.2	7,422	84	120,833	16	2.2	1,440
None	465,633	33.4	0.9	1,255,622	18	25,100,751	20	4.4	1,393,561
<b>Maintenance Assistance Status</b>									
Cash	160,476	32.8	1.1	519,452	23	11,341,396	22	3.1	489,410
Medically needy	1,175	26.2	1.2	5,281	54	240,228	45	4.1	4,489
Poverty related	227,413	33.6	0.8	537,669	14	9,620,316	18	7.5	676,190
Other/unknown	78,702	34.7	0.9	212,829	18	4,188,022	20	4.7	226,933

Table ND11

Nondual Beneficiaries

Source: Data for this table are from the MAX 2003 file for Georgia, released by CMS in 04/2007. This table was produced on 11/01/2007.

- a. Table ND.11 includes the beneficiaries represented by Cell K of Table 1. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2003.
- b. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.
- c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- d. Please refer to footnote f on Table 1 for methodology used to determine use of nursing facilities.

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.12

USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D  
 AMONG NONDUALS PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC<sup>a,b</sup>  
 GEORGIA, 2003

Beneficiary Characteristics	Number Rx per Benefit Month	Rx \$ per Benefit Month	\$ per Rx	Barbiturate \$ per Benefit Month	Benzodiazepine \$ per Benefit Month	Number of Benefit Months
All	0.1	\$2	\$20	\$0	\$0	12,578,532
<b>Age</b>						
5 and younger	0.1	3	18	0	0	4,107,866
6-14	0.1	2	24	0	0	3,931,012
15-20	0.1	2	25	0	0	1,614,342
21-44	0.1	2	21	0	0	2,168,489
45-64	0.2	4	17	0	1	696,793
65-74	0.2	3	12	0	0	34,958
75-84	0.2	2	11	0	1	17,146
85 and older	0.3	3	11	0	1	7,917
Unknown	0.0	0	0	0	0	9
<b>Basis of Eligibility<sup>c</sup></b>						
Aged	0.2	2	12	0	1	55,047
Disabled	0.2	5	27	0	1	1,616,161
Adults	0.1	1	14	0	0	2,057,249
Children	0.1	2	19	0	0	8,850,075
Unknown	0.0	0	0	0	0	0
<b>Gender</b>						
Female	0.1	2	20	0	0	7,196,729
Male	0.1	2	20	0	0	5,381,680
Unknown	0.0	0	9	0	0	123
<b>Race</b>						
White	0.1	3	20	0	0	4,851,702
African American	0.1	1	19	0	0	6,593,444
Other/unknown	0.1	3	23	0	1	1,133,386
<b>Use of Nursing Facilities<sup>d</sup></b>						
Entire year	0.6	8	14	1	3	21,124
Part year	0.5	8	16	0	2	14,358
None	0.1	2	20	0	0	12,543,050
<b>Maintenance Assistance Status</b>						
Cash	0.1	2	22	0	0	4,716,891
Medically needy	0.2	10	45	0	1	24,846
Poverty related	0.1	2	18	0	0	5,891,407
Other/unknown	0.1	2	20	0	0	1,945,388

Source: Data for this table are from the MAX 2003 file for Georgia, released by CMS in 04/2007. This table was produced on 11/01/2007.

- a. Table ND.12 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2003.
- b. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.
- c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- d. Please refer to footnote f on Table 1 for methodology used to determine use of nursing facilities.

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.



TABLE ND.13  
 USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D  
 FOR SELECTED DRUG CATEGORIES AMONG NONDUALS<sup>a,b,c</sup>  
 GEORGIA, 2003

Drug Category	Number of Users	Rx \$ per User	Total Rx \$	Rx \$ as a Percentage of All Part D Excluded Rx \$		Total Number Rx.	\$ per Rx	Number Rx as a Percentage of All Part D Excluded Rx	
				Excluded Rx \$	100.0 %			Excluded Rx	100.0 %
<b>All</b>	<b>522,091</b>	<b>\$49</b>	<b>\$25,389,962</b>	<b>100.0 %</b>	<b>1,275,231</b>	<b>\$20</b>	<b>100.0 %</b>	<b>1,275,231</b>	<b>100.0 %</b>
Anorexia or weight loss/gain	55	236	12,976	0.1	139	93	0.0	139	0.0
Fertility drugs	8	89	709	0.0	11	64	0.0	11	0.0
Drugs for cosmetic purposes	217	14	3,083	0.0	326	9	0.0	326	0.0
Cough and cold medications	373,144	44	16,330,730	64.3	855,908	19	67.1	855,908	67.1
Vitamins and minerals	20,137	78	1,564,115	6.2	84,561	18	6.6	84,561	6.6
Non-prescription drugs	68,283	11	781,139	3.1	132,462	6	10.4	132,462	10.4
Barbiturates	3,366	43	145,329	0.6	25,990	6	2.0	25,990	2.0
Benzodiazepines	38,329	73	2,786,060	11.0	134,828	21	10.6	134,828	10.6
Other Part D Excl Rx Drugs	18,552	203	3,765,821	14.8	41,006	92	3.2	41,006	3.2

Source: Data for this table are from the MAX 2003 file for Georgia, released by CMS in 04/2007. This table was produced on 11/01/2007.

- a. Table ND.13 includes the beneficiaries represented by Cell K of Table 1. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2003. A user is a beneficiary who had at least one prescription filled for a Part D excluded drug in 2003. A beneficiary who used drugs from two or more Part D excluded categories was counted as a user for each category. Therefore, the sum of users across drug categories may exceed the total number of individual users as noted on Table ND11.
  - b. Includes OTC drugs as well as prescription drugs.
  - c. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.
- Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

APPENDIX TABLE A.1

CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY<sup>a, b</sup>  
 NONDUAL BENEFICIARIES, GEORGIA, 2003

Beneficiary Characteristics	Number of Beneficiaries					Number of Benefit Months				
	All	Aged	Disabled	Adults	Unknown	All	Aged	Disabled	Adults	Unknown
<b>All</b>	<b>1,397,022</b>	<b>5,963</b>	<b>151,025</b>	<b>281,777</b>	<b>0</b>	<b>12,578,532</b>	<b>55,047</b>	<b>1,616,161</b>	<b>2,057,249</b>	<b>0</b>
<b>Age</b>										
5 and younger	457,748	0	10,819	64	446,865	4,107,866	0	112,671	475	3,994,720
6-14	404,245	0	23,252	249	380,744	3,931,012	0	260,811	1,761	3,668,440
15-20	181,642	69	14,311	37,154	130,108	1,614,342	602	159,778	271,753	1,182,209
21-44	276,820	1,035	43,600	231,693	492	2,168,489	9,463	468,759	1,686,007	4,260
45-64	70,497	977	56,957	12,547	16	696,793	9,024	590,951	96,677	141
65-74	3,478	1,672	1,784	21	1	34,958	14,940	19,900	116	2
75-84	1,735	1,464	268	2	1	17,146	14,172	2,946	16	12
85 and older	856	746	34	46	30	7,917	6,846	345	435	291
Unknown	1	0	0	1	0	0	0	0	9	0
<b>Gender</b>										
Female	816,882	4,636	77,397	260,190	474,659	7,196,729	42,823	839,537	1,920,396	4,393,973
Male	580,118	1,327	73,627	21,587	483,577	5,381,680	12,224	776,612	136,853	4,455,991
Unknown	22	0	1	0	21	123	0	12	0	111
<b>Race</b>										
White	567,008	2,568	52,686	125,822	385,932	4,851,702	22,803	550,953	833,550	3,444,396
African American	703,422	1,669	66,293	147,452	488,008	6,593,444	15,154	719,328	1,173,336	4,685,626
Other/unknown	126,592	1,726	32,046	8,503	84,317	1,133,386	17,090	345,880	50,363	720,053
<b>Use of Nursing Facilities<sup>c</sup></b>										
Entire year	2,021	677	1,344	0	0	21,124	6,879	14,245	0	0
Part year	1,440	347	1,088	4	1	14,358	3,049	11,261	36	12
None	1,393,561	4,939	148,593	281,773	958,256	12,543,050	45,119	1,590,655	2,057,213	8,850,063
<b>Maintenance Assistance Status</b>										
Cash	489,410	1,508	125,397	127,791	234,714	4,716,891	16,784	1,388,528	1,020,358	2,291,221
Medically needy	4,489	807	3,623	1	58	24,846	5,524	19,186	1	135
Poverty related	676,190	2,127	36	109,162	564,865	5,891,407	19,478	349	658,766	5,212,814
Other/unknown	226,933	1,521	21,969	44,823	158,620	1,945,388	13,261	208,098	378,124	1,345,905
<b>Managed Care (MC) Status</b>										
Fee-for-service (FFS) all year	1,397,022	5,963	151,025	281,777	958,257	12,578,532	55,047	1,616,161	2,057,249	8,850,075
FFS part year, with Rx claims	0	0	0	0	0	0	0	0	0	0
FFS part year, no Rx claims	0	0	0	0	0	0	0	0	0	0
MC all year, with Rx claims	0	0	0	0	0	0	0	0	0	0
MC all year, no Rx claims	0	0	0	0	0	0	0	0	0	0

Source: Data for this table are from the MAX 2003 file for Georgia, released by CMS in 04/2007. This table was produced on 11/01/2007.

a. Table A.1 includes the beneficiaries represented by Cell J of Table 1. Benefit months are months during which beneficiaries had pharmacy benefit coverage.

b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.

c. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene Mo(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; MC = managed care; Rx = pharmacy benefit.

APPENDIX TABLE A.2  
 MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS<sup>a</sup>  
 NONDUAL BENEFICIARIES, GEORGIA, 2003

	Beneficiaries and			Excluded from Cell K of Table 1 Number of Beneficiaries
	Benefit Months in Cell J of Table 1 Number of Beneficiaries	Included in Cell K of Table 1 Number of Beneficiaries	Number of Benefit Months	
<b>All</b>	<b>1,397,022</b>	<b>1,397,022</b>	<b>12,578,532</b>	<b>0</b>
Fee-for-service (FFS) all year	1,397,022	1,397,022	12,578,532	0
FFS part year, with Rx claims	0	0	0	0
FFS part year, with no Rx claims	0	0	0	0
Managed care (MC) all year, with Rx claims	0	0	0	0
MC all year, with no Rx claims	0	0	0	0

Source: Data for this table are from the MAX 2003 file for Georgia, released by CMS in 04/2007. This table was produced on 11/01/2007.

a. Benefit months are months during which beneficiaries had pharmacy benefit coverage.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; MC = managed care; Rx = pharmacy benefit.